INTRODUCTION
============

Malaria is a disease caused by the parasite, *Plasmodium*. Malaria is a global health problem, with an estimated two million cases and over five hundred deaths reported each year, a high percentage of which occur in the sub-Saharan Africa ([@ref44]). Malaria in humans is caused by the *Plasmodium* species *Plasmodium falciparum*, *Plasmodium ovale*, *Plasmodium malariae*, and *Plasmodium vivax*. A recent study has shown two non-recombining species of *Ovale* exist (*Ovale curtisi* and *Ovale wallikeri*) ([@ref23]), which are non-sympatric in nature ([@ref30]). Malaria in children in sub-Saharan Africa is primarily caused by *P. falciparum* ([@ref43]). *P. falciparum* is also the most abundant *Plasmodium* species in Africa and is responsible for about 98% of malaria death in Nigeria ([@ref44]). Malaria in Nigeria accounts for a quarter of all cases in Africa, and has about 30∼50% morbidity and 25% mortality in infants ([@ref31]). *P. falciparum* is also the cause of almost all the symptoms of severe malaria ([@ref26]). *Anopheles gambiae* is the major carrier of malaria, particularly in Nigeria. *Anopheles melas* is popularly located in the coastal areas ([@ref31]). Malarial infection is usually associated with production of huge quantities of reactive oxygen species (ROS) by both the host and parasite, therefore inducing oxidative stress in the host system. If left untreated, prolonged infection can therefore result in further systemic complications and even death ([@ref1]; [@ref3]).

In order to safe guard people, several drugs have been manufactured that are all effective within certain time frames. However, constant use of these drugs leads in resistance by *P. falciparum*. Although these drugs are effective against the parasite, most are too expensive for the common man who lives below average. Distribution of the drugs is also another important factor since they cannot be accessed in remote villages. Further, several fake drugs that are harmful to several organs of the body have been produced, increasing the need to focus efforts on the use of medicinal herbs for treatment of malaria ([@ref5]; [@ref2]). The efficacy of some of these herbs has been shown, however only a few has received attention regarding their individual safety for human organs ([@ref7]; [@ref42]).

The family of Eucalyptus (Myrtaceous) plants are source of biologically active compounds, such as steroids, tannins, polyphenolics, glycosides, terpenes, alkaloids, flavonoids, saponins, lignins, vitamin C, fatty acids, phenolics, triterpenoid, flavones, anthocyanin, anthraquinone, coumarins, cardiac glycosides, terpenoids, and polyphenols, including flavonoids, phloroglucinol derivatives, and volatile oils ([@ref20]; [@ref18]; [@ref12]; [@ref14]). These compounds have been employed locally for the treatment of ailments, such as wounds, tumors, dyspepsia, and malaria ([@ref46]; [@ref20]; [@ref10]; [@ref24]; [@ref47]; [@ref8]; [@ref15]; [@ref22]; [@ref4]).

This study was carried out to examine the bioactive components of *Eucalyptus camaldulensis* aqueous leaf extracts and their protective effects on liver and renal functions in individuals infected with malaria using a *Plasmodium berghei*-induced albino mouse model of malarial infection.

MATERIALS AND METHODS
=====================

Plant collection
----------------

Fresh *E. camaldulensis* leaves were collected from the wide growing habitat in Oviorie-Ovu, Ethiope East Local Government Area, Delta State, Nigeria and were verified by the Botany Department, Faculty of Sciences, Delta State University, Abraka, Delta State, Nigeria. The leaves were air-dried to crisp in a laboratory at 28±2℃ for two weeks until a constant weight. Leaves were then ground to a fine powder using sterilized machine (SBM-2977, M-Tech, Osaka, Japan).

Preparation of the extracts
---------------------------

One hundred grams of powdered leaves was weighed and soaked for 24 h in 400 mL of distilled water in a conical flask. The aqueous extract was then sieved and concentrated at 45℃ to a paste-like solution using rotary evaporator. The extract was further concentrated until dry by using a water bath. The extract was kept in an air-tight container and stored at 4℃ for later use.

Experimental design
-------------------

***Animal acclimatization*:** Thirty-six adult albino male mice with weight 25 to 30 g were bred and purchased from the animal unit, Faculty of Basic Medical Sciences, Laboratory Animal Facility, Delta State University, Abraka, Delta State, Nigeria. Mice were maintained in normal and standard laboratory conditions of room temperature (24±2℃), a relative humidity (46±6%), a 12 h light/dark cycle, and with adequate ventilation for the duration of the experiment. The animals were first acclimatized for 10∼14 days. During this period, mice were allowed uninhibited access to food and water before they were randomly divided into different groups. Mice received the standard grower's mash diet (Top Feed, Sapele, Delta State, Nigeria).

All experimental animals received normal feed and water *ad libitum* during the period of the experiments. The experiments were conducted in compliance with "Guide for Care and Use of Laboratory Animals" of the Department of Biochemistry, Delta State University (approval no.: BCH/REC/2018/006).

***Collection and inoculation of experimental animals*:** Malarial parasites (*P. berghei*) were obtained from the Nigerian Institute of Medical Research Yaba, Lagos State, Nigeria. Mice were infected with parasites by obtaining parasitized blood from the cut tail tip of an infected (donor) mice. The experimental design was as follows:

**Group NC:** Control Group (uninfected mice injected with phosphate buffered saline).

**Group PC:** Untreated malarial infected mice group.

**Group C1:** Malarial infected mice treated with 100 mg/kg of *E. camaldulensis*.

**Group C2:** Malarial infected mice treated with 200 mg/kg of *E. camaldulensis*.

**Group C3:** Malarial infected mice treated with 300 mg/kg of *E. camaldulensis*.

**Group STD:** Malarial infected mice treated with a standard antimalarial drug (0.68/8.4 mg/kg of Artemether/Lumefantrine).

***Sample collection*:** Mice were sacrificed and blood samples were obtained by ocular puncture using capillary tubes into lithium heparin sample containers. Blood samples were centrifuged at 4,000 rpm for 10 min, and the serum was collected and preserved in a refrigerator at 4℃ for biochemical analysis.

Haematological/biochemical analyses
-----------------------------------

Whole blood samples were used to determine the degree of parasitemia (malarial parasite load) in infected mice, both before and after treatment. Biochemical analyses were carried out on serum samples collected to estimate the activities/levels of major liver function biomakers, serum electrolytes and renal function biomarkers such as: alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transferase (GGT), alkaline phosphatase (ALP) activity, total protein (TP), total bilirubin (TB), direct bilirubin (DB), serum sodium, chloride, phosphorous, chloride, urea, uric acid, and serum creatinine levels. Assays were carried out using previously described standard procedures ([@ref38]; [@ref40]; [@ref6]; [@ref11]; [@ref32]).

Statistical analysis
--------------------

All data are expressed as mean±standard error of mean (SEM). Statistical comparisons were performed by one-way analysis of variance (ANOVA) followed by Dunnett's or Tukey's post-hoc tests using GraphPad Prism software (version 8.0.2, GraphPad Prism Software, San Diego, CA, USA). Difference were considered significant at *P*\<0.05.

RESULTS
=======

Phytochemical constituents
--------------------------

The qualitative and quantitative analysis of the aqueous leaf extracts of *E. camaldulensis* showed that it is rich in several phytochemicals, including polyphenols, saponins, and flavonoids ([Table 1](#T1){ref-type="table"} and 2).

Changes in parasitemia cell level
---------------------------------

The changes in the amount of parasitemia cells in normal and *P. berghei* malaria-infected mice at day 0, before infection and after treatment are as showed in [Table 3](#T3){ref-type="table"}. A noticeable elevation in parasitemia level in control mice was observed at day 4 compared with baseline (0 day). Infected mice who received *E. camaldulensis* and the standard antimalarial drug had reduced parasitemea levels. Mice in group C2 has a significantly higher parasitemia count compared with the other groups. Administration of the plant extracts at 100 mg/kg, 200 mg/kg, 300 mg/kg, and the standard antimalarial drug remarkably decreased parasitemia levels in these groups.

Malaria-induced alterations in serum electrolytes
-------------------------------------------------

There was a significant (*P*\<0.05) decrease in serum levels of sodium, chloride, and serum phosphorus in PC compared with those in the NC ([Fig. 1A](#F1){ref-type="fig"} and 1B). Administration of *E. camaldulensis* (especially at 300 mg/kg) and the standard antimalarial drug, significantly (*P*\<0.05) elevated levels of these electrolytes compared with mice in the PC group. In contrast, serum calcium levels were significantly (*P*\<0.05) increased in the PC group compared with both the NC group and all groups that received *E. camaldulensis* extracts or antimalarial drugs ([Fig. 1B](#F1){ref-type="fig"}).

Malaria-induced alterations in liver and renal function biomarkers
------------------------------------------------------------------

Induction of malaria significantly (*P*\<0.05) increased the activities of liver function biomarkers in the PC group compared with the mice in the NC group ([Table 4](#T4){ref-type="table"}). However, the elevated activities of liver function enzyme biomarkers (serum ALT, AST, ALP, and GGT) significantly (*P*\<0.05) decreased upon administration of different doses of the *E. camaldulensis* extract (groups C1, C2, and C3) compared with the PC group. A similar trend was also observed in TB and DB levels in mice in groups C1, C2, C3, and STD compared with the PC group ([Table 4](#T4){ref-type="table"}).

The kidney function biomarkers investigated (serum urea, uric acid, and creatinine levels) were also markedly increased (*P*\<0.05) in untreated PC compared with the NC, extract-treated (C1, C2, and C3) and STD groups ([Table 5](#T5){ref-type="table"}).

DISCUSSION
==========

In this study, the abundance of various phytochemicals detected qualitatively and quantitatively in *E. camaldulensis* support its medicinal value. Glycoside, micronutrients, proteins, and amino acids were not detected in the plant extracts, supporting its medicinal efficacy and established pathways of action against several diseases ([@ref17]; [@ref21]; [@ref34]; [@ref13]). Detection of tannins, alkaloids, and terpenoids strengthens its medicinal value ([@ref17]). Mice infected with malarial parasites and treated with *E. camaldulensis* extracts showed impeded parasite growth compared with parasite-infected controls.

The average amount of parasitaemia observed in STD group was 13.27%, thus there was little parasite development. In mice treated with *E. camaldulensis*, the two most effective doses (group C2 and C3) resulted in an average of 38.80% parasitaemia. Although, orthodox antimalarial drugs are most effective, management of malaria is associated with numerous challenges such as drug resistance, being of substandard quality, having a high cost, and not being readily available to the common man, especially those in remote villages; therefore, use of these plant extracts should be encouraged. Since *E. camaldulensis* extracts (group C2 and C3) suppressed parasitaemia to a mean value of 38.80%, *E. camaldulensis* could serve as a replacement for conventional antimalarial drugs that lose their effectiveness due to drug resistance.

The severity of malaria infections can be determined by both renal and hepatic malfunction. The clinical manifestation of renal involvement is accompanied by infection with *P. falciparum* and *P. malariae* ([@ref25]), and may be accountable for an immune complex-mediated glomerular disease resulting in nephrotic syndrome. Other consequences range from urinary sediment abnormalities, mild proteinuria, and electrolyte alterations, to serious renal failure with metabolic acidosis ([@ref35]). In addition, renal tubular aberrations are related to *P. falciparum* infection, and complications may include mild to severe tubular necrosis and acute renal failure, followed by frequent oliguria and hypercatabolism ([@ref16]).

This study demonstrated that *E. camaldulensis* leaf extracts generally reduced the activities of liver function enzymes (serum ALP, AST, ALT, and GGT) and levels of kidney function biomarkers (serum creatinine, serum urea, and uric acid). Further, these extracts possess blood schizontocidal activity, which is in line with results from suppressive tests ([Table 4](#T4){ref-type="table"} and 5). When mice infected with *P. berghei* were treated with anti-malarial drugs, parasitemia was reduced to almost unnoticeable levels ([@ref37]). We also noticed a remarkable elevation in the levels of serum ALP, ALT, and AST activity in mice infected with *P. berghei* compared with both the control and treated groups. Similar to the renal function biomarkers (such as serum creatinine, urea, and serum uric acid levels) elevated levels of liver function enzymes, such as serum ALT, AST, ALP, and GGT, are indicative of impaired organ function. In the present study, administration of *E. camaldulensis* (especially at a dose of 300 mg/kg) and standard antimalarial drugs (Artemether/Lumefantrine) markedly decreased the activities of serum ALP, ALT, and AST compared with mice in the untreated malaria-infected group. This indicates the plant extracts have ameliorative effects on malaria-induced liver function impairment. Creatinine and urea are non-protein nitrogenous wastes that are removed from the body through glomerular filtration. Creatinine is produced internally by creatine kinase in muscle (Onyesom et al. 2015). Measurements of these compounds in serum (creatinine, urea, and uric acid) alone, or alongside some electrolytes, has been described in literature for assessing renal function impairment ([@ref45]; [@ref9]; [@ref41]; [@ref33]; [@ref19]; [@ref28]). In this study, there was a noticeable rise in levels of serum urea, uric acid, and creatinine in mice infected with *P. berghei* compared with mice in the control and treated groups, probably due to inflammation and interstitial nephritis induced by malarial parasites. The observed modulatory nature of the extracts on the activities of liver enzymes and levels of kidney biomarkers may be due to destruction of the parasites and/or antioxidant properties of the plant extracts, perhaps originating from its active components (phytochemicals) ([@ref16]; [@ref27]). It has also been reported that some plants exhibit antiplasmodial activity by thwarting protein synthesis ([@ref37]), perhaps due to the presence of certain phytochemical constituents. Vitamins A, C, and E and flavonoids may act as primary antioxidant or free radical scavengers that fight against oxidative damage induced by the malaria parasite. Hence, *E. camaldulensis* extracts containing appreciable amounts of these phytochemicals might show antiplasmodial activity via any of these mechanisms.

The human body requires electrolytes for its normal physiological functions ([@ref39]; [@ref36]; [@ref29]). In this study, malaria-induced alterations in levels of serum electrolytes (serum sodium, chloride, calcium, and phosphorus) were ameliorated in mice treated with various concentrations of *E. camaldulensis* extracts and the standard antimalarial drug compared with mice in the healthy control group ([Fig. 1A](#F1){ref-type="fig"} and 1B). Some symptoms, such as twitching and weakness (fatigue), are sometimes associated with electrolyte imbalance; however, if left unchecked, seizures, and alterations in heart rhythm may follow ([@ref39]). This could be because muscles and neurons depend on the balance and movement of electrolytes through bodily fluids within, outside, or between cells for proper function ([@ref39]; [@ref36]; [@ref29]).

The findings of this research show that aqueous leaf extracts of *E. camaldulensis* reduce elevated levels of serum creatinine, urea, and uric acid, and decrease elevated levels of liver biomarkers in malaria-induced mice. These findings suggest the potential clinical importance of *E. camaldulensis* against malaria, and show aqueous leaf extracts may ameliorate or protect against impairment of liver and renal functions, which are sometimes associated with malarial parasite attack in some subjects. Although the extracts also showed ameliorative effects against changes in serum electrolytes levels, its antimalarial effect was most significant at a dose range of 200∼300 mg/kg body weight. Based on these findings, we conclude that subjects who use *E. camaldulensis* locally for treatment of malaria would benefit from both its antimalarial effects and its ameliorative effect against impairment of liver and kidney functions caused by malarial parasites during critical stages of the infection.

**AUTHOR DISCLOSURE STATEMENT**

The authors declare no conflict of interest.

![Effect of *Eucalyptus camaldulensis* aqueous extracts on levels of (A) serum Na and Cl and (B) serum Ca and P levels in *Plasmodium berghei*-infected mice. NC, normal control group; PC, untreated *P. berghei*-infected alone; C1, infected mice treated with *E. camaldulensis* (100 mg/kg); C2, infected mice treated with *E. camaldulensis* (200 mg/kg); C3, infected mice treated with *E. camaldulensis* (300 mg/kg) aqueous; STD, infected mice treated with standard antimalarial drug. \*Significantly differed from group PC at *P*\<0.05 using Dunnett's post-hoc test.](PNFS-25-058-f1){#F1}

###### 

Qualitative analysis of phytochemical constituents of *Eucalyptus camaldulensis*

  Phytochemical        *Eucalyptus camaldulensis* (red gum)
  -------------------- --------------------------------------
  Saponin              ++
  Tannin               +++
  Terpenes             +++
  Flavonoid            \+
  Phlobatannins        \+
  Alkaloid             −
  Gycosides            −
  Resin                +++
  Phenol               +++
  Micronutrients       −
  Steroids             −
  Proteins             −
  Carbohydrates        ++
  Amino acids          −
  Fixed oil and fats   \+
  Non reducing sugar   +++

+, mildly present; ++, highly present; +++, more highly present; −, absent or non-detectable.

###### 

Total phenol and flavonoid contents of *Eucalyptus camaldulensis*

  Phytoconstituent            *Eucalyptus camaldulensis*
  --------------------------- ----------------------------
  Total phenol (g/100 g DW)   1.52±0.63
  Total flavonoid (μg CE/g)   67.91±5.01

Values are expressed as mean±SEM.

DW, dry weight; CE, catechin equivalent.

###### 

Antimalarial effect of *Eucalyptus camaldulensis* aqueous extracts on mice infected with *Plasmodium berghei*

  Group   Parasitemia day 0   Parasitemia day 4   Percent parasitemia (%) on day 4   Percent decrease in parasitemia (%) on day 4
  ------- ------------------- ------------------- ---------------------------------- ----------------------------------------------
  NC      0                   0                   0                                  0
  PC      17.50±0.49^a^       16.70±1.44^a^       95.43±8.62^a^                      4.57
  C1      11.50±1.02^b^       9.50±2.14^b^        82.61±22.53^b^                     17.39
  C2      12.25±0.76^b^       4.67±0.33^c^        38.12±7.07^c^                      61.88
  C3      11.40±0.98^b^       4.50±0.41^c^        39.47±9.11^c^                      60.53
  STD     11.30±1.43^b^       1.50±0.11^d^        13.27±7.33^d^                      86.73

Values are expressed as mean±SEM (n=6).

Values not sharing a common letter (a-d) differ significantly at *P*\<0.05.

NC, normal control group; PC, untreated *P. berghei*-infected mice; C1, infected mice treated with *E. camaldulensis* (100 mg/kg); C2, infected mice treated with *E. camaldulensis* (200 mg/kg); C3, infected mice treated with *E. camaldulensis* (300 mg/kg) aqueous; STD, infected mice treated with standard antimalarial drug.

###### 

Effect of *Eucalyptus camaldulensis* aqueous extract treatment on levels of liver function biomarkers in malaria-induced mice

  Group   ALT (U/L)       AST (U/L)       ALP (U/L)       GGT (U/L)       TB (mg/dL)     DB (mg/dL)
  ------- --------------- --------------- --------------- --------------- -------------- --------------------------------------------
  NC      15.30±0.14^b^   46.66±0.58^b^   40.92±6.04^c^   63.00±2.00^c^   0.72±0.07^b^   0.72±0.14[ns](#t4fn3){ref-type="table-fn"}
  PC      22.80±4.33^a^   58.10±0.82^a^   60.88±17.9^a^   87.50±14.8^a^   2.95±2.75^a^   1.45±0.91
  C1      16.95±1.48^b^   41.52±7.65^c^   59.99±17.5^a^   76.50±8.69^b^   1.55±1.17^a^   0.92±0.15
  C2      16.62±0.68^b^   39.32±6.17^c^   49.88±3.43^b^   79.00±6.21^b^   0.77±0.88^b^   0.82±0.45
  C3      16.83±1.75^b^   37.76±10.8^c^   45.53±9.56^c^   66.33±5.03^c^   0.76±1.36^b^   0.88±0.56
  STD     10.80±1.00^c^   23.65±4.21^d^   42.94±4.02^c^   69.00±4.96^c^   1.07±0.70^b^   0.97±0.17

Values are expressed as mean±SEM (n=6).

Values not sharing a common letter (a-d) differ significantly at *P*\<0.05.

Not significant.

NC, normal control group; PC, untreated *Plasmodium berghei*-infected alone; C1, infected mice treated with *E. camaldulensis* (100 mg/kg); C2, infected mice treated with *E. camaldulensis* (200 mg/kg); C3, infected mice treated with *E. camaldulensis* (300 mg/kg) aqueous; STD, infected mice treated with standard antimalarial drug; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatise; GGT, γ-glutamyl transferase; TB, total bilirubin; DB, direct bilirubin.

###### 

Effect of *Eucalyptus camaldulensis* aqueous extract treatment on levels of serum creatinine, urea, and uric acid in malaria-induced mice

  Group   Creatinine (mg/dL)   Urea (mg/dL)    Uric acid (mg/dL)
  ------- -------------------- --------------- -------------------
  NC      1.14±0.39^d^         24.32±2.41^e^   2.25±1.73^d^
  PC      2.20±0.70^a^         50.18±22.1^a^   4.90±0.49^a^
  C1      1.90±0.39^a^         40.04±3.15^b^   4.30±2.46^b^
  C2      2.07±0.09^a^         36.85±9.19^c^   3.85±0.62^c^
  C3      1.63±0.20^b^         30.98±15.3^d^   3.36±0.55^c^
  STD     1.52±0.27^c^         26.54±8.25^e^   2.30±0.29^d^

Values are expressed as mean±SEM (n=6).

Values not sharing a common letter (a-e) differ significantly at *P*\<0.05.

NC, normal control group; PC, untreated *Plasmodium berghei*-infected alone; C1, infected mice treated with *E. camaldulensis* (100 mg/kg); C2, infected mice treated with *E. camaldulensis* (200 mg/kg); C3, infected mice treated with *E. camaldulensis* (300 mg/kg) aqueous; STD, infected mice treated with standard antimalarial drug.
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